Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa H Lancaster

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Multidisciplinary Respiratory Medicine|December 19, 2018
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosisLisa H Lancaster
Frontiers in Medicine|November 1, 2021
Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)Carla R Copeland, Lisa H Lancaster
Respiratory Medicine|May 19, 2007
Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physiciansHarold R Collard, James E Loyd, Talmadge E King, et al.
Chest|July 8, 2015
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key QuestionsKeith C Meyer, Sonye K Danoff, Lisa H Lancaster, et al.
Pulmonary Therapy|March 21, 2020
Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational SurveyLisa H Lancaster, Claudia Valenzuela, Wendi Mason, et al.
Respiration; International Review of Thoracic Diseases|September 13, 2017
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)Ulrich Costabel, Carlo Albera, Lisa H Lancaster, et al.
Respiratory Research|March 15, 2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Marilyn K Glassberg, et al.
Chest|July 2, 2009
Obstructive sleep apnea is common in idiopathic pulmonary fibrosisLisa H Lancaster, Wendi R Mason, James A Parnell, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Multidisciplinary Respiratory Medicine|December 19, 2018
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosisLisa H Lancaster
Frontiers in Medicine|November 1, 2021
Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)Carla R Copeland, Lisa H Lancaster
Respiratory Medicine|May 19, 2007
Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physiciansHarold R Collard, James E Loyd, Talmadge E King, et al.
Chest|July 8, 2015
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key QuestionsKeith C Meyer, Sonye K Danoff, Lisa H Lancaster, et al.
Pulmonary Therapy|March 21, 2020
Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational SurveyLisa H Lancaster, Claudia Valenzuela, Wendi Mason, et al.
Respiration; International Review of Thoracic Diseases|September 13, 2017
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)Ulrich Costabel, Carlo Albera, Lisa H Lancaster, et al.
Respiratory Research|March 15, 2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Marilyn K Glassberg, et al.
Chest|July 2, 2009
Obstructive sleep apnea is common in idiopathic pulmonary fibrosisLisa H Lancaster, Wendi R Mason, James A Parnell, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Pageof 4